Indegene P/E Ratio
Indegene (INDGN) P/E ratio is 34.74 (High), EPS (TTM) ₹16.72, current price ₹600.10 on NSE vs historical average P/E of 33.87 (100.0th percentile) — Very High - High growth expectations or significantly overvalued.
Current Valuation Metrics
Valuation Signal
Sector Context
Earnings Breakdown (TTM)
INDGN P/E Ratio — Valuation Signal & Historical Context
Indegene P/E 34.74 vs historical average 33.87, range 33.12–34.62 — signal: Overvalued. Also explore INDGN price trends to track price trends across different timeframes.
- Stock appears overvalued with PE of 34.74, suggesting caution for new investments
- Trading at discount to sector average PE of 56.91
Indegene P/E Ratio Historical Trend
INDGN annual price-to-earnings ratio — 2 years, EPS and year-end price. Current P/E 34.74 vs historical average 33.87. For live price, revenue and the complete fundamental profile, see Indegene share price today.
INDGN Historical P/E Ratio — EPS, Year-End Price & Valuation
Indegene annual P/E ratio, EPS (₹), year-end price and valuation category on NSE.
| Year | P/E Ratio | EPS (₹) | Year-end Price (₹) | Exchange | Valuation |
|---|---|---|---|---|---|
| 2025 | 33.12 | 18.32 | ₹606.80 | NSE | High |
| 2024 | 34.62 | 16.49 | ₹570.90 | NSE | High |
INDGN vs Healthcare Peers — P/E Ratio Comparison
Indegene P/E 34.74 vs Healthcare average 56.91, median 31.66 — range 1.99–747.21.
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 1.99 | ₹66 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Colinz Laboratories | COLINZ | 3.27 | ₹9 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹59 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.03 | ₹6,361 | Low |
| Dipna Pharmachem | DPL | 4.65 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.95 | ₹67 | Low |
| Shelter Pharma | SHELTER | 5.71 | ₹56 | Low |
| GKB Ophthalmics | GKB | 5.9 | ₹33 | Low |
| Kabra Drugs | KABRADG | 6.29 | ₹49 | Low |